Table 3 NCI recommendation for the use of tocilizumab in patients with CAR T-cell-associated CRS (according to [9])
Tocilizumab 4 to 8 mg/kg i.v. (1-h infusion, maximum 800 mg) | |
|---|---|
(1) Decrease of LVEF <40% assessed by echocardiogram | |
(2) Increase of creatinine >2.5-fold compared to baseline | |
(3) Norepinephrine support (>2 μg/min) for 48 h since start of vasopressors (even if non-continuous administration) | |
(4) Decrease of systolic blood pressure <90 mmHG despite vasopressor support | |
(5) Severe dyspnea potentially requiring mechanical ventilation | |
(6) APTT >2× UNL | |
(7) Persisting elevation (>5× UNL) of creatinine kinase longer than 48 h |